BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 26643568)

  • 1. Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.
    Narayanan S; Srinivas S; Feldman D
    Nat Rev Urol; 2016 Jan; 13(1):47-60. PubMed ID: 26643568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.
    Hu J; Chen Q
    Int Urol Nephrol; 2017 Mar; 49(3):369-380. PubMed ID: 27987128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
    Kim W; Ryan CJ
    Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-arm androgen blockade for advanced prostate cancer: a review.
    Desai MH; Parsi M; Potdar RR
    Med Oncol; 2021 May; 38(7):75. PubMed ID: 34032938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of adrenal derived androgens in castration resistant prostate cancer.
    Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
    J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of hydrocortisone esters targeting androgen and glucocorticoid receptors in prostate cancer in vitro.
    Peřina M; Kiss A; Mernyák E; Mada L; Schneider G; Jorda R
    J Steroid Biochem Mol Biol; 2023 May; 229():106269. PubMed ID: 36773737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconsideration of progression to CRPC during androgen deprivation therapy.
    Mizokami A; Namiki M
    J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Imamura Y; Sadar MD
    Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Androgen biosynthesis in castration-resistant prostate cancer: Advances in studies].
    Chen B; Cao DH; Guo JB; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Mar; 25(3):265-271. PubMed ID: 32216246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
    Puhr M; Hoefer J; Eigentler A; Ploner C; Handle F; Schaefer G; Kroon J; Leo A; Heidegger I; Eder I; Culig Z; Van der Pluijm G; Klocker H
    Clin Cancer Res; 2018 Feb; 24(4):927-938. PubMed ID: 29158269
    [No Abstract]   [Full Text] [Related]  

  • 17. [Mechanisms of drug resistance in endocrinotherapy for castration-resistant prostate cancer].
    Bo B; Guo JB; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2021 Feb; 27(2):167-171. PubMed ID: 34914335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in the studies of androgen metabolism and de novo androgen synthesis in castration resistant prostate cancer].
    Wang B; Wu KJ; He DL
    Zhonghua Nan Ke Xue; 2013 Aug; 19(8):736-41. PubMed ID: 24010211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F; Fizazi K
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.